Head to Head Survey: Revance Therapeutics (RVNC) & Its Competitors

Revance Therapeutics (NASDAQ: RVNC) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Revance Therapeutics to related companies based on the strength of its profitability, earnings, dividends, institutional ownership, analyst recommendations, valuation and risk.

Insider and Institutional Ownership

76.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 18.9% of Revance Therapeutics shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Revance Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Revance Therapeutics -37,161.00% -67.85% -57.91%
Revance Therapeutics Competitors -5,443.85% -164.39% -36.43%

Risk & Volatility

Revance Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Revance Therapeutics’ peers have a beta of 2.36, indicating that their average stock price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares Revance Therapeutics and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Revance Therapeutics $300,000.00 -$89.27 million -9.08
Revance Therapeutics Competitors $290.27 million $35.99 million 56.05

Revance Therapeutics’ peers have higher revenue and earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for Revance Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revance Therapeutics 0 1 7 0 2.88
Revance Therapeutics Competitors 1134 3426 11925 240 2.67

Revance Therapeutics presently has a consensus target price of $45.00, indicating a potential upside of 30.43%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.70%. Given Revance Therapeutics’ peers higher possible upside, analysts clearly believe Revance Therapeutics has less favorable growth aspects than its peers.


Revance Therapeutics peers beat Revance Therapeutics on 8 of the 13 factors compared.

About Revance Therapeutics

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply